Partners & Collaborators

We welcome partners and collaborators to help create cell and gene therapies with the capacity to cure. Join us in bringing new and better treatments to patients in need.


Our partnering strategy

At Poseida, we are always looking for new ways to develop cell and gene therapies for the most profound health challenges. We know these challenges can’t be solved by one person – or even one organization. It takes collaboration. That’s why we strive to partner with leaders in industry, academia, and government who share our passion and drive.

What we’re looking for

We are actively seeking collaborators to help develop and commercialize new cell and gene therapeutics with the capacity to cure. By working together and leveraging the power of our platform in new and innovative ways, we have the opportunity to change the future of medicine.  

Areas for potential collaboration:

  • Autologous CAR-T or TCR-T therapies
  • Allogeneic CAR-T or TCR-T therapies
  • In vivo liver-directed gene therapies
  • New therapeutic applications of our piggyBac® gene insertion technology, Cas CLOVER™ gene editing technology, and nanoparticle delivery technology
  • Opportunities to leverage our technology in new therapeutic areas outside oncology and liver-directed gene therapy
  • Novel technologies that further enable our current approaches to developing cell and gene therapies

Recent collaborations

Contact us

Are you interested in partnering with Poseida?

Please contact us.


We have entered into a research collaboration and exclusive license agreement with Takeda Pharmaceutical Company Limited to utilize Poseida’s piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of novel gene therapies. Read more

We have entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel “off-the-shelf” cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. Read more